ArticlePharmaceutical research2018
A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 58 citations in OpenAlex.
- Curcumin derivatives with 1,5-diaryl-3-oxo-1,4-pentadiene: novel dual-function lead compounds showing anticancer and MDR reversal effects.RSC advances · 2026Article
- Pharmaceutical Cocrystals in Drug-Delivery Technologies: Advances from Rational Design to Therapeutic Applications.Pharmaceutics · 2026Review
- Magnetic melamine cross-linked polystyrene-alt-malic anhydride copolymer: Synthesis, characterization, paclitaxel delivery, cytotoxic effects on human ovarian and breast cancer cells.Oncology research · 2025Article
- Better together: biomimetic nanomedicines for high performance tumor therapy.Beilstein journal of nanotechnology · 2025Review
- Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment.International journal of pharmaceutics: X · 2024Review
- Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy.Frontiers in pharmacology · 2024Review
- The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics.Discover oncology · 2023Review
- A SWOT analysis of nano co-crystals in drug delivery: present outlook and future perspectives.RSC advances · 2023Review
- Targeted delivery of paclitaxel drug using polymer-coated magnetic nanoparticles for fibrosarcoma therapy: in vitro and in vivo studies.Scientific reports · 2023Article
- Gut-Thyroid axis: How gut microbial dysbiosis associated with euthyroid thyroid cancer.Journal of Cancer · 2022Article
- Delivery strategies of amphotericin B for invasive fungal infections.Acta pharmaceutica Sinica. B · 2021Review
- Gut microbial dysbiosis and its association with esophageal cancer.Journal of applied biomedicine · 2021Article
- Homotype-Targeted Biogenic Nanoparticles to Kill Multidrug-Resistant Cancer Cells.Pharmaceutics · 2020Article
- Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Drug Nanorod-Mediated Intracellular Delivery of microRNA-101 for Self-sensitization via Autophagy Inhibition.Nano-micro letters · 2019Article
- Advances in nanomedicine for the treatment of ankylosing spondylitis.International journal of nanomedicine · 2019Review
- Amorphous Nanosuspensions Aggregated from Paclitaxel⁻Hemoglobulin Complexes with Enhanced Cytotoxicity.Pharmaceutics · 2018Article
- Pharmaceutical Dispersion Techniques for Dissolution and Bioavailability Enhancement of Poorly Water-Soluble Drugs.Pharmaceutics · 2018Review
- Membrane Loaded Copper Oleate PEGylated Liposome Combined with Disulfiram for Improving Synergistic Antitumor Effect In Vivo.Pharmaceutical research · 2018Article
- Drug-delivering-drug platform-mediated potent protein therapeuticsTheranostics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeA multidrug resistance (MDR) modulator, disulfiram (DSF), was incorporated into pure paclitaxel (PTX) nanoparticles to construct a smart paclitaxel-disulfiram nanococrystals (PTX-DSF Ns) stabilized by β-lactoglobulin (β-LG), with the aim to reverse MDR and therefore enhnce cytotoxicity towards Taxol-resistant A549 cells (A549/TAX).
methodPTX-DSF Ns was prepared by antisolvent precipitation method. Flow cytometry was used to determine the cell uptake, drug efflux inhibition, cell cycle phase arrest and apoptosis. MDR-1 gene expression level was detected by real time quantitative PCR and gel electrophoresis.
resultsPTX-DSF Ns prepared from the optimized formulation had an optimum diameter of 160 nm, was stable and had a high drug-loading capacity. Importantly, the uptake of PTX-DSF Ns in A549/TAX cells was 14-fold greater than the uptake of PTX Ns. Furthermore, PTX-DSF Ns promoted 5-folds increase in apoptosis, enabled 7-folds reduction in the IC
conclusionPTX-DSF Ns with a precise mass ratio offer efficient cytotoxicity against Taxol-resistant cells and a novel approach for codelivery and sensitizing MDR cancer to chemotherapy. In addition, the use of nanosuspensions as a combined treatment provides a new research avenue for nanosuspensions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.